Scroll

vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4223	163521-12-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vilazodone viibryd vilazodone hydrochloride vilazodone HCl	A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT. Molecular weight: 441.54 Formula: C26H27N5O2 CLOGP: 4.33 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 102.29 ALOGS: -3.56 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vilazodone
viibryd
vilazodone hydrochloride
vilazodone HCl

A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.

Molecular weight: 441.54
Formula: C26H27N5O2
CLOGP: 4.33
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 102.29
ALOGS: -3.56
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
Vd (Volume of distribution)	4.85 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.76 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	15.66 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2011	FDA	FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	255.28	20.04	122	5843	62299	63420758
Abnormal dreams	143.47	20.04	49	5916	10467	63472590
Hallucination	123.44	20.04	72	5893	54745	63428312
Persistent genital arousal disorder	99.18	20.04	18	5947	268	63482789
Anxiety	94.56	20.04	109	5856	217432	63265625
Serotonin syndrome	90.23	20.04	47	5918	28635	63454422
Agitation	80.95	20.04	57	5908	59700	63423357
Nightmare	76.70	20.04	37	5928	19157	63463900
Sleep paralysis	72.93	20.04	16	5949	644	63482413
Mania	68.77	20.04	30	5935	12337	63470720

Showing 1 to 10 of 33 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	142.18	33.14	61	1928	40327	34914615
Serotonin syndrome	141.05	33.14	50	1939	19883	34935059
Completed suicide	91.20	33.14	61	1928	98107	34856835
Mania	52.83	33.14	20	1969	9491	34945451
Sexual dysfunction	49.03	33.14	17	1972	6286	34948656
Anxiety	40.30	33.14	38	1951	99390	34855552
Overdose	35.36	33.14	34	1955	91025	34863917
Irritability	34.61	33.14	20	1969	24670	34930272

Showing 1 to 8 of 8 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Suicidal ideation	213.97	21.28	105	5475	76235	79662573
Serotonin syndrome	138.28	21.28	66	5514	44961	79693847
Completed suicide	125.44	21.28	117	5463	245650	79493158
Persistent genital arousal disorder	98.00	21.28	17	5563	264	79738544
Abnormal dreams	94.44	21.28	34	5546	11378	79727430
Anxiety	85.96	21.28	96	5484	248416	79490392
Hallucination	66.48	21.28	52	5528	85693	79653115
Mania	66.04	21.28	30	5550	18230	79720578
Anger	58.31	21.28	27	5553	17135	79721673
Irritability	55.40	21.28	35	5545	41109	79697699

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N06AX24	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35941	serotonin agonists
CHEBI has role	CHEBI:50949	SSRI
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs

Showing 1 to 10 of 14 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hyponatremia	contraindication	89627008
Seizure disorder	contraindication	128613002
Suicidal	contraindication	267073005
Serotonin syndrome	contraindication	371089000

Showing 1 to 10 of 10 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.56	acidic
pKa2	13.13	acidic
pKa3	8.58	Basic
pKa4	1.41	Basic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
10MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
20MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
20MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY
40MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	Jan. 31, 2023	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
40MG	VIIBRYD	ABBVIE	N022567	Jan. 21, 2011	RX	TABLET	ORAL	July 31, 2023	PEDIATRIC EXCLUSIVITY

Showing 1 to 6 of 6 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	IC50	9.30	IUPHAR	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	AGONIST	Ki	9.70	IUPHAR	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.41	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	IC50	7.15	IUPHAR
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	AGONIST	IC50	6.50	IUPHAR
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	6.53	CHEMBL
5-hydroxytryptamine receptor 4	GPCR	Q13639	5HT4R_HUMAN	AGONIST	IC50	6.60	IUPHAR
Adrenergic receptor alpha-2	GPCR	P08913 P18089 P18825	ADA2A_HUMAN ADA2B_HUMAN ADA2C_HUMAN		IC50	5.22	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	IC50	6.18	IUPHAR
Adrenergic receptor alpha-1	GPCR	P25100 P35348 P35368	ADA1D_HUMAN ADA1A_HUMAN ADA1B_HUMAN		IC50	5.70	CHEMBL

Showing 1 to 10 of 26 entries

Previous1 2 3Next

External reference:

Show entries

Search:

ID	Source
013753	NDDF
013754	NDDF
1086768	RXNORM
163521-08-2	SECONDARY_CAS_RN
179494	MMSL
27744	MMSL
359491	MMSL
4030483	VUID
4030483	VANDF
4030484	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1110	TABLET	10 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1110	TABLET	10 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1120	TABLET	20 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1120	TABLET	20 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1140	TABLET	40 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	0456-1140	TABLET	40 mg	ORAL	NDA	32 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4624	TABLET	40 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4624	TABLET	40 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4627	TABLET	20 mg	ORAL	NDA	29 sections
VIIBRYD	HUMAN PRESCRIPTION DRUG LABEL	1	55154-4627	TABLET	20 mg	ORAL	NDA	29 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next